SUSTAINED VIROLOGICAL RESPONSE IN HCV PATIENTS TREATED WITH DACLATASVIR plus SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN: A MULTICENTER, FIELD-PRACTICE EXPERIENCE

被引：0
|
作者：
Sacco, Rodolfo
Salomoni, Elena
Parodi, Sara
Gianni, Elena
Gragnani, Laura
Andreotti, Giovanni
Zignego, Anna Linda
Gattai, Riccardo
Vivaldi, Ilo
De Luca, Andrea
Bartolozzi, Dario
Cinelli, Roberta
Pozzi, Marco
Coco, Barbara
Tapete, Gherardo
Forte, Paolo
Puntili, Rachele
Ricciardi, Liana
Sani, Spartaco
Luchi, Sauro
Brunetto, Maurizia Rossana
Valoriani, Beatrice
Riccardi, Maria Piera
Nencioni, Cesira
Aquilini, Donatella
Nerli, Alessandro
Esperti, Francesco
Mazzotta, Francesco
Fabiani, Silvia
Menichetti, Francesco
Bresci, Giampaolo
Colombatto, Piero
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)33694-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1523
引用
收藏
页码：S1097 / S1097
页数：1
相关论文
共 50 条
  • [41] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM
    Petersen, J.
    Welzel, T.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S781 - S782
  • [42] Increasing ribavirin doses improves the sustained virological response in HCV patients not responding to pegylated interferon and ribavirin
    Conti, F.
    Lorenzini, S.
    Riili, A.
    Cursaro, C.
    Scuteri, A.
    Loggi, E.
    Bernardi, M.
    Andreone, P.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S92 - S92
  • [43] Treatment Failure With Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Treatment Naive Patients With Chronic Hepatitis C Without Cirrhosis
    Afzal, Muhammad
    Tarar, Shahida Husain
    Shah, Syed Muhammad Ali
    Butt, Zamir
    Ajmal, Muhammad
    Younis, Irfan
    Talat, Syed Usama
    Akhtar, Hina
    Ali, Javeria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S560 - S561
  • [44] The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
    Abdelkawy, K. S.
    El-Haggar, S. M.
    Ziada, D. H.
    Ebaid, N. F.
    El-Magd, M. A.
    Elbarbry, F. A.
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [45] Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
    Butt, Zamir
    Shah, Syed Muhammad Ali
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (02) : 409 - 413
  • [46] Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response
    Fernandez-Rodriguez, Conrado M.
    Alonso, Sonia
    Martinez, Stella M.
    Forns, Xavier
    Sanchez-Tapias, Jose M.
    Rincon, Diego
    Rodriguez-Caravaca, Gil
    Barcena, Rafael
    Serra, Miguel A.
    Romero-Gomez, Manuel
    Fernandez, Inmaculada
    Garcia-Samaniego, Javier
    Fuente, Javier
    Sola, Ricard
    Moreno-Otero, Ricardo
    Planas, Ramon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (10): : 2164 - 2172
  • [47] High virological efficacy of sofosbuvir/daclatasvir plus flat dose ribavirin in genotype 3 cirrhotic patients: a real life study
    Giannelli, Valerio
    Messina, Vincenzo
    palitti, valerio pace
    Vignally, Pascal
    tarquini, pierluigi
    Izzi, Antonio
    Marignani, Massimo
    Pompili, Maurizio
    Ettorre, Giuseppe M.
    Pellicelli, Adriano M.
    HEPATOLOGY, 2017, 66 : 816A - 816A
  • [48] Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC)
    Sulkowski, M. S.
    Gardiner, D. F.
    Rodriguez-Torres, M.
    Reddy, K. R.
    Hassanein, T.
    Jacobson, I.
    Lawitz, E.
    Lok, A. S.
    Hinestrosa, F.
    Thuluvath, P. J.
    Schwartz, H.
    Nelson, D. R.
    Everson, G. T.
    Eley, T.
    Wind-Rotolo, M.
    Huang, S. P.
    Gao, M.
    Mcphee, F.
    Hernandez, D.
    Sherman, D.
    Hindes, R.
    Symonds, W.
    Pasquinelli, C.
    Grasela, D. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 155 - 155
  • [49] SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
    Sulkowski, M. S.
    Gardiner, D. F.
    Rodriguez-Torres, M.
    Reddy, K. R.
    Hassanein, T.
    Jacobson, I.
    Lawitz, E.
    Lok, A. S.
    Hinestrosa, F.
    Thuluvath, P. J.
    Schwartz, H.
    Nelson, D. R.
    Everson, G. T.
    Eley, T.
    Wind-Rotolo, M.
    Huang, S. -P.
    Gao, M.
    McPhee, F.
    Hernandez, D.
    Sherman, D.
    Hindes, R.
    Symonds, W.
    Pasquinelli, C.
    Grasela, D. M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S570 - S570
  • [50] Daclatasvir exposure does not explain lower sustained virologic response rates in cirrhotic patients with HCV genotype 3 following 12 weeks of daclatasvir plus sofosbuvir treatment
    Eley, Timothy
    Wang, Reena
    Huang, Shu-Pang
    Gandhi, Yash
    Cirincione, Brenda
    LaCreta, Frank
    Garimella, Tushar
    HEPATOLOGY, 2015, 62 : 567A - 568A
12345